Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TGTX Tg Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: TGTX
Price (delayed)
$33.86
Market cap
$5.32B
P/E Ratio
211.63
Dividend/share
N/A
EPS
$0.16
Enterprise value
$5.39B
TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active
Highlights
The company's net income has surged by 85% YoY
Tg Therapeutics's EPS has surged by 78% YoY
The quick ratio has increased by 33% QoQ but it has decreased by 3% YoY
TGTX's debt has soared by 131% YoY
The gross margin has decreased by 6% YoY
Key stats
What are the main financial stats of TGTX
Market
Valuations
Earnings
Shares outstanding
157.07M
Market cap
$5.32B
Enterprise value
$5.39B
Price to earnings (P/E)
211.63
Price to book (P/B)
23.7
Price to sales (P/S)
14.96
EV/EBIT
108.62
EV/EBITDA
108.47
EV/Sales
16.38
Revenue
$329M
Gross profit
$290.52M
Operating income
$41.93M
Net income
$23.38M
EBIT
$49.62M
EBITDA
$49.69M
Free cash flow
-$40.56M
Per share
Balance sheet
Liquidity
EPS
$0.16
EPS diluted
$0.15
Free cash flow per share
-$0.28
Book value per share
$1.43
Revenue per share
$2.26
TBVPS
$3.98
Total assets
$577.69M
Total liabilities
$355.33M
Debt
$252.56M
Equity
$222.36M
Working capital
$475.68M
Debt to equity
1.14
Current ratio
6.25
Quick ratio
4.87
Net debt/EBITDA
1.44
Margins
Efficiency
Dividend
EBITDA margin
15.1%
Gross margin
88.3%
Net margin
7.1%
Operating margin
12.7%
Return on assets
4.8%
Return on equity
12.4%
Return on invested capital
11.7%
Return on capital employed
10.2%
Return on sales
15.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TGTX stock price
How has the Tg Therapeutics stock price performed over time
Intraday
-2.84%
1 week
-25.37%
1 month
-4.7%
1 year
97.78%
YTD
12.49%
QTD
-14.13%
Financial performance
How have Tg Therapeutics's revenue and profit performed over time
Revenue
$329M
Gross profit
$290.52M
Operating income
$41.93M
Net income
$23.38M
Gross margin
88.3%
Net margin
7.1%
The operating income has soared by 103% YoY
The company's net income has surged by 85% YoY
Tg Therapeutics's operating margin has increased by 44% YoY
The revenue rose by 41% YoY and by 24% QoQ
Price vs fundamentals
How does TGTX's price correlate with its fundamentals
Growth
What is Tg Therapeutics's growth rate over time
Valuation
What is Tg Therapeutics stock price valuation
P/E
211.63
P/B
23.7
P/S
14.96
EV/EBIT
108.62
EV/EBITDA
108.47
EV/Sales
16.38
Tg Therapeutics's EPS has surged by 78% YoY
The equity is up by 39% year-on-year and by 16% since the previous quarter
The P/B is 35% above the last 4 quarters average of 17.5 and 8% above the 5-year quarterly average of 22.0
The P/S is 100% below the 5-year quarterly average of 4567.8 but 45% above the last 4 quarters average of 10.3
The revenue rose by 41% YoY and by 24% QoQ
Efficiency
How efficient is Tg Therapeutics business performance
Tg Therapeutics's return on sales has increased by 37% YoY
The company's return on equity fell by 3.9% YoY
TGTX's ROIC is down by 2.5% YoY
The ROA has grown by 2.1% YoY
Dividends
What is TGTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TGTX.
Financial health
How did Tg Therapeutics financials performed over time
The total assets is 63% higher than the total liabilities
Tg Therapeutics's total liabilities has surged by 110% YoY but it has decreased by 10% QoQ
The total assets has soared by 75% YoY
TGTX's debt is 14% higher than its equity
TGTX's debt has soared by 131% YoY
The debt to equity has soared by 68% YoY but it has contracted by 13% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.